GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » Cash Flow from Investing

HQL (abrdn Life Sciences Investors) Cash Flow from Investing : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is abrdn Life Sciences Investors Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the six months ended in Mar. 2024, abrdn Life Sciences Investors spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, abrdn Life Sciences Investors gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the six months ended in Mar. 2024.


abrdn Life Sciences Investors Cash Flow from Investing Historical Data

The historical data trend for abrdn Life Sciences Investors's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

abrdn Life Sciences Investors Cash Flow from Investing Chart

abrdn Life Sciences Investors Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash Flow from Investing
Get a 7-Day Free Trial - - - - -

abrdn Life Sciences Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

abrdn Life Sciences Investors Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

abrdn Life Sciences Investors's Cash Flow from Investing for the fiscal year that ended in Sep. 2023 is calculated as:

abrdn Life Sciences Investors's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


abrdn Life Sciences Investors  (NYSE:HQL) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

abrdn Life Sciences Investors's purchase of property, plant, equipment for the six months ended in Mar. 2024 was $0.00 Mil. It means abrdn Life Sciences Investors spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

abrdn Life Sciences Investors's sale of property, plant, equipment for the six months ended in Mar. 2024 was $0.00 Mil. It means abrdn Life Sciences Investors gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

abrdn Life Sciences Investors's purchase of business for the six months ended in Mar. 2024 was $0.00 Mil. It means abrdn Life Sciences Investors spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

abrdn Life Sciences Investors's sale of business for the six months ended in Mar. 2024 was $0.00 Mil. It means abrdn Life Sciences Investors gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

abrdn Life Sciences Investors's purchase of investment for the six months ended in Mar. 2024 was $0.00 Mil. It means abrdn Life Sciences Investors spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

abrdn Life Sciences Investors's sale of investment for the six months ended in Mar. 2024 was $0.00 Mil. It means abrdn Life Sciences Investors gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

abrdn Life Sciences Investors's net Intangibles purchase and sale for the six months ended in Mar. 2024 was $0.00 Mil. It means abrdn Life Sciences Investors paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

abrdn Life Sciences Investors's cash from discontinued investing activities for the six months ended in Mar. 2024 was 0.00 Mil. It means abrdn Life Sciences Investors paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

abrdn Life Sciences Investors's cash from other investing activities for the six months ended in Mar. 2024 was $0.00 Mil. It means abrdn Life Sciences Investors paid $0.00 Mil for other investing activities.


abrdn Life Sciences Investors Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


abrdn Life Sciences Investors Business Description

Traded in Other Exchanges
N/A
Address
1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.
Executives
Bill Maher director 600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino director C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
Kathleen Goetz director 1310 OAK VALLEY CIRCLE, POLK CITY IA 50226
Todd Reit director C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
James Joseph O'connor other: Director of Adviser C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc. other: Adviser 1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar officer: VP and Chief Legal Officer 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols other: Director of Adviser 1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard officer: President ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy officer: Secretary and Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari officer: Treasurer and CFO 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson officer: Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina officer: Chief Compliance Officer & VP 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103

abrdn Life Sciences Investors Headlines

From GuruFocus

Tekla Life Sciences Investors Declares Stock Distribution

By Business Wire Business Wire 08-17-2020

Tekla Life Sciences Investors Declares Stock Distribution

By Business Wire Business Wire 05-18-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 06-30-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 12-31-2020

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 12-30-2022

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 05-17-2022

Tekla Life Sciences Investors Paid Distribution

By Business Wire 06-30-2023

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 08-16-2022

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 06-30-2020